{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:10:41Z","timestamp":1787317841447,"version":"build-2736575974"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T00:00:00Z","timestamp":1665360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T00:00:00Z","timestamp":1665360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["BT\/PR40153\/137\/8\/2021"],"award-info":[{"award-number":["BT\/PR40153\/137\/8\/2021"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s11030-022-10540-3","type":"journal-article","created":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T08:42:31Z","timestamp":1665391351000},"page":"2053-2071","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Pharmacophore-based virtual screening of ZINC database, molecular modeling and designing new derivatives as potential HDAC6 inhibitors"],"prefix":"10.1007","volume":"27","author":[{"given":"Priya","family":"Poonia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3154-7335","authenticated-orcid":false,"given":"Madhu","family":"Chopra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,10]]},"reference":[{"key":"10540_CR1","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.2174\/0929867324666170921101947","volume":"26","author":"Y Li","year":"2019","unstructured":"Li Y, Li Z, Zhu W-G (2019) Molecular mechanisms of epigenetic regulators as activatable targets in cancer theranostics. Curr Med Chem 26:1328\u20131350. https:\/\/doi.org\/10.2174\/0929867324666170921101947","journal-title":"Curr Med Chem"},{"key":"10540_CR2","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/j.ejmech.2017.10.040","volume":"143","author":"X-X Wang","year":"2018","unstructured":"Wang X-X, Wan R-Z, Liu Z-P (2018) Recent advances in the discovery of potent and selective HDAC6 inhibitors. Eur J Med Chem 143:1406\u20131418. https:\/\/doi.org\/10.1016\/j.ejmech.2017.10.040","journal-title":"Eur J Med Chem"},{"key":"10540_CR3","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/B978-0-12-380866-0.60013-7","volume":"70","author":"C Biancotto","year":"2010","unstructured":"Biancotto C, Frig\u00e8 G, Minucci S (2010) Histone modification therapy of cancer. Adv Genet 70:341\u2013386. https:\/\/doi.org\/10.1016\/B978-0-12-380866-0.60013-7","journal-title":"Adv Genet"},{"key":"10540_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.molonc.2007.01.001","volume":"1","author":"S Ropero","year":"2007","unstructured":"Ropero S, Esteller M (2007) The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 1:19\u201325. https:\/\/doi.org\/10.1016\/j.molonc.2007.01.001","journal-title":"Mol Oncol"},{"key":"10540_CR5","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a019521","volume":"8","author":"JE Audia","year":"2016","unstructured":"Audia JE, Campbell RM (2016) Histone modifications and cancer. Cold Spring Harb Perspect Biol 8:a019521. https:\/\/doi.org\/10.1101\/cshperspect.a019521","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10540_CR6","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1053\/j.gastro.2015.07.011","volume":"149","author":"Y Okugawa","year":"2015","unstructured":"Okugawa Y, Grady WM, Goel A (2015) Epigenetic alterations in colorectal cancer: emerging biomarkers. Gastroenterology 149:1204-1225.e12. https:\/\/doi.org\/10.1053\/j.gastro.2015.07.011","journal-title":"Gastroenterology"},{"key":"10540_CR7","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13045-018-0654-9","volume":"11","author":"T Li","year":"2018","unstructured":"Li T, Zhang C, Hassan S et al (2018) Histone deacetylase 6 in cancer. J Hematol Oncol 11:111. https:\/\/doi.org\/10.1186\/s13045-018-0654-9","journal-title":"J Hematol Oncol"},{"key":"10540_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2014.12.050","volume":"359","author":"M Hao","year":"2015","unstructured":"Hao M, Song F, Du X et al (2015) Advances in targeted therapy for unresectable melanoma: New drugs and combinations. Cancer Lett 359:1\u20138. https:\/\/doi.org\/10.1016\/j.canlet.2014.12.050","journal-title":"Cancer Lett"},{"key":"10540_CR9","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.molcel.2007.05.033","volume":"27","author":"X Zhang","year":"2007","unstructured":"Zhang X, Yuan Z, Zhang Y et al (2007) HDAC6 modulates cell motility by altering the acetylation level of cortactin. Mol Cell 27:197\u2013213. https:\/\/doi.org\/10.1016\/j.molcel.2007.05.033","journal-title":"Mol Cell"},{"key":"10540_CR10","doi-asserted-by":"publisher","first-page":"21579","DOI":"10.18632\/oncotarget.15375","volume":"8","author":"R Basu","year":"2017","unstructured":"Basu R, Wu S, Kopchick JJ (2017) Targeting growth hormone receptor in human melanoma cells attenuates tumor progression and epithelial mesenchymal transition via suppression of multiple oncogenic pathways. Oncotarget 8:21579\u201321598. https:\/\/doi.org\/10.18632\/oncotarget.15375","journal-title":"Oncotarget"},{"key":"10540_CR11","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3233\/JAD-2012-120727","volume":"33","author":"L Zhang","year":"2013","unstructured":"Zhang L, Sheng S, Qin C (2013) The role of HDAC6 in Alzheimer\u2019s disease. J Alzheimers Dis 33:283\u2013295. https:\/\/doi.org\/10.3233\/JAD-2012-120727","journal-title":"J Alzheimers Dis"},{"key":"10540_CR12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/alzrt241","volume":"6","author":"M-L Selenica","year":"2014","unstructured":"Selenica M-L, Benner L, Housley SB et al (2014) Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition. Alzheimers Res Ther 6:12. https:\/\/doi.org\/10.1186\/alzrt241","journal-title":"Alzheimers Res Ther"},{"key":"10540_CR13","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1091\/mbc.e10-03-0200","volume":"21","author":"G Du","year":"2010","unstructured":"Du G, Liu X, Chen X et al (2010) Drosophila histone deacetylase 6 protects dopaminergic neurons against {alpha}-synuclein toxicity by promoting inclusion formation. Mol Biol Cell 21:2128\u20132137. https:\/\/doi.org\/10.1091\/mbc.e10-03-0200","journal-title":"Mol Biol Cell"},{"key":"10540_CR14","doi-asserted-by":"publisher","first-page":"E5178","DOI":"10.1073\/pnas.1415589111","volume":"111","author":"PM McLendon","year":"2014","unstructured":"McLendon PM, Ferguson BS, Osinska H et al (2014) Tubulin hyperacetylation is adaptive in cardiac proteotoxicity by promoting autophagy. Proc Natl Acad Sci U S A 111:E5178-5186. https:\/\/doi.org\/10.1073\/pnas.1415589111","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Suppl 1","key":"10540_CR15","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1007\/s10637-010-9596-y","volume":"28","author":"M Dickinson","year":"2010","unstructured":"Dickinson M, Johnstone RW, Prince HM (2010) Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. Invest New Drugs 28(Suppl 1):S3-20. https:\/\/doi.org\/10.1007\/s10637-010-9596-y","journal-title":"Invest New Drugs"},{"key":"10540_CR16","doi-asserted-by":"publisher","first-page":"505","DOI":"10.2174\/138161208783885353","volume":"14","author":"KV Butler","year":"2008","unstructured":"Butler KV, Kozikowski AP (2008) Chemical origins of isoform selectivity in histone deacetylase inhibitors. Curr Pharm Des 14:505\u2013528. https:\/\/doi.org\/10.2174\/138161208783885353","journal-title":"Curr Pharm Des"},{"key":"10540_CR17","doi-asserted-by":"publisher","first-page":"6936","DOI":"10.1021\/jm0505011","volume":"48","author":"D-F Wang","year":"2005","unstructured":"Wang D-F, Helquist P, Wiech NL, Wiest O (2005) Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human Class I histone deacetylases. J Med Chem 48:6936\u20136947. https:\/\/doi.org\/10.1021\/jm0505011","journal-title":"J Med Chem"},{"key":"10540_CR18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1073\/pnas.011405598","volume":"98","author":"R Furumai","year":"2001","unstructured":"Furumai R, Komatsu Y, Nishino N et al (2001) Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc Natl Acad Sci U S A 98:87\u201392. https:\/\/doi.org\/10.1073\/pnas.011405598","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10540_CR19","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.bcp.2012.06.014","volume":"84","author":"S Dallavalle","year":"2012","unstructured":"Dallavalle S, Pisano C, Zunino F (2012) Development and therapeutic impact of HDAC6-selective inhibitors. Biochem Pharmacol 84:756\u2013765. https:\/\/doi.org\/10.1016\/j.bcp.2012.06.014","journal-title":"Biochem Pharmacol"},{"key":"10540_CR20","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1021\/acs.jmedchem.9b01540","volume":"63","author":"JD Osko","year":"2020","unstructured":"Osko JD, Porter NJ, Narayana Reddy PA et al (2020) Exploring structural determinants of inhibitor affinity and selectivity in complexes with histone deacetylase 6. J Med Chem 63:295\u2013308. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b01540","journal-title":"J Med Chem"},{"key":"10540_CR21","doi-asserted-by":"publisher","first-page":"13459","DOI":"10.1073\/pnas.1718823114","volume":"114","author":"NJ Porter","year":"2017","unstructured":"Porter NJ, Mahendran A, Breslow R, Christianson DW (2017) Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors. Proc Natl Acad Sci U S A 114:13459\u201313464. https:\/\/doi.org\/10.1073\/pnas.1718823114","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10540_CR22","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1248\/cpb.57.897","volume":"57","author":"T Suzuki","year":"2009","unstructured":"Suzuki T (2009) Explorative study on isoform-selective histone deacetylase inhibitors. Chem Pharm Bull (Tokyo) 57:897\u2013906. https:\/\/doi.org\/10.1248\/cpb.57.897","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"10540_CR23","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1111\/cbdd.13488","volume":"93","author":"M Sharma","year":"2019","unstructured":"Sharma M, Jha P, Verma P, Chopra M (2019) Combined comparative molecular field analysis, comparative molecular similarity indices analysis, molecular docking and molecular dynamics studies of histone deacetylase 6 inhibitors. Chem Biol Drug Des 93:910\u2013925. https:\/\/doi.org\/10.1111\/cbdd.13488","journal-title":"Chem Biol Drug Des"},{"key":"10540_CR24","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1080\/07391102.2019.1590241","volume":"38","author":"J Liu","year":"2020","unstructured":"Liu J, Zhu Y, He Y et al (2020) Combined pharmacophore modeling, 3D-QSAR and docking studies to identify novel HDAC inhibitors using drug repurposing. J Biomol Struct Dyn 38:533\u2013547. https:\/\/doi.org\/10.1080\/07391102.2019.1590241","journal-title":"J Biomol Struct Dyn"},{"key":"10540_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/ph3092751","author":"S Subramanian","year":"2010","unstructured":"Subramanian S, Bates SE, Wright JJ et al (2010) Clinical toxicities of histone deacetylase inhibitors. Pharmaceuticals (Basel, Switzerland). https:\/\/doi.org\/10.3390\/ph3092751","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"key":"10540_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-020-2586-x","volume":"11","author":"J Auzmendi-Iriarte","year":"2020","unstructured":"Auzmendi-Iriarte J, Saenz-Anto\u00f1anzas A, Mikelez-Alonso I et al (2020) Characterization of a new small-molecule inhibitor of HDAC6 in glioblastoma. Cell Death Dis 11:1\u201314. https:\/\/doi.org\/10.1038\/s41419-020-2586-x","journal-title":"Cell Death Dis"},{"key":"10540_CR27","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.01154-06","author":"Y Zhang","year":"2008","unstructured":"Zhang Y, Kwon S, Yamaguchi T et al (2008) Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol Cell Biol. https:\/\/doi.org\/10.1128\/MCB.01154-06","journal-title":"Mol Cell Biol"},{"key":"10540_CR28","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1021\/acs.jmedchem.5b01493","volume":"59","author":"J Senger","year":"2016","unstructured":"Senger J, Melesina J, Marek M et al (2016) Synthesis and biological investigation of oxazole hydroxamates as highly selective histone deacetylase 6 (HDAC6) inhibitors. J Med Chem 59:1545\u20131555. https:\/\/doi.org\/10.1021\/acs.jmedchem.5b01493","journal-title":"J Med Chem"},{"key":"10540_CR29","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.compbiolchem.2018.10.016","volume":"77","author":"AI Uba","year":"2018","unstructured":"Uba AI, Yelek\u00e7i K (2018) Pharmacophore-based virtual screening for identification of potential selective inhibitors of human histone deacetylase 6. Comput Biol Chem 77:318\u2013330. https:\/\/doi.org\/10.1016\/j.compbiolchem.2018.10.016","journal-title":"Comput Biol Chem"},{"key":"10540_CR30","doi-asserted-by":"publisher","first-page":"15704","DOI":"10.1073\/pnas.1313893110","volume":"110","author":"J-H Lee","year":"2013","unstructured":"Lee J-H, Mahendran A, Yao Y et al (2013) Development of a histone deacetylase 6 inhibitor and its biological effects. Proc Natl Acad Sci U S A 110:15704\u201315709. https:\/\/doi.org\/10.1073\/pnas.1313893110","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10540_CR31","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1080\/07391102.2018.1434833","volume":"37","author":"Y Wang","year":"2019","unstructured":"Wang Y, Yang L, Hou J et al (2019) Hierarchical virtual screening of the dual MMP-2\/HDAC-6 inhibitors from natural products based on pharmacophore models and molecular docking. J Biomol Struct Dyn 37:649\u2013670. https:\/\/doi.org\/10.1080\/07391102.2018.1434833","journal-title":"J Biomol Struct Dyn"},{"key":"10540_CR32","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1021\/acschemneuro.8b00405","volume":"10","author":"A Zeb","year":"2019","unstructured":"Zeb A, Park C, Rampogu S et al (2019) Structure-based drug designing recommends HDAC6 inhibitors to attenuate microtubule-associated tau-pathogenesis. ACS Chem Neurosci 10:1326\u20131335. https:\/\/doi.org\/10.1021\/acschemneuro.8b00405","journal-title":"ACS Chem Neurosci"},{"key":"10540_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2020.103679","volume":"97","author":"H Song","year":"2020","unstructured":"Song H, Niu X, Quan J et al (2020) Discovery of specific HDAC6 inhibitor with anti-metastatic effects in pancreatic cancer cells through virtual screening and biological evaluation. Bioorg Chem 97:103679. https:\/\/doi.org\/10.1016\/j.bioorg.2020.103679","journal-title":"Bioorg Chem"},{"key":"10540_CR34","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1080\/07391102.2020.1743760","volume":"39","author":"G Yan","year":"2021","unstructured":"Yan G, Li D, Zhong X et al (2021) Identification of HDAC6 selective inhibitors: pharmacophore based virtual screening, molecular docking and molecular dynamics simulation. J Biomol Struct Dyn 39:1928\u20131939. https:\/\/doi.org\/10.1080\/07391102.2020.1743760","journal-title":"J Biomol Struct Dyn"},{"key":"10540_CR35","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jcim.5b00559","author":"T Sterling","year":"2022","unstructured":"Sterling T, Irwin JJ (2022) ZINC 15\u2014ligand discovery for everyone. J Chem Inf Model. https:\/\/doi.org\/10.1021\/acs.jcim.5b00559","journal-title":"J Chem Inf Model"},{"key":"10540_CR36","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1002\/jcc.20291","volume":"26","author":"D Van Der Spoel","year":"2005","unstructured":"Van Der Spoel D, Lindahl E, Hess B et al (2005) GROMACS: fast, flexible, and free. J Comput Chem 26:1701\u20131718. https:\/\/doi.org\/10.1002\/jcc.20291","journal-title":"J Comput Chem"},{"key":"10540_CR37","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.3109\/10428194.2011.577259","volume":"52","author":"EA Eklund","year":"2011","unstructured":"Eklund EA, Platanias LC (2011) Inhibition of histone deacetylase 6 as a therapeutic strategy for acute lymphocytic leukemia. Leuk Lymphoma 52:1421\u20131422. https:\/\/doi.org\/10.3109\/10428194.2011.577259","journal-title":"Leuk Lymphoma"},{"key":"10540_CR38","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1021\/jm200773h","volume":"55","author":"JH Kalin","year":"2012","unstructured":"Kalin JH, Butler KV, Akimova T et al (2012) Second-generation histone deacetylase 6 inhibitors enhance the Immunosuppressive effects of Foxp3+ T-regulatory cells. J Med Chem 55:639\u2013651. https:\/\/doi.org\/10.1021\/jm200773h","journal-title":"J Med Chem"},{"key":"10540_CR39","doi-asserted-by":"publisher","first-page":"7067","DOI":"10.1016\/j.bmcl.2010.09.100","volume":"20","author":"PK Gupta","year":"2010","unstructured":"Gupta PK, Reid RC, Liu L et al (2010) Inhibitors selective for HDAC6 in enzymes and cells. Bioorg Med Chem Lett 20:7067\u20137070. https:\/\/doi.org\/10.1016\/j.bmcl.2010.09.100","journal-title":"Bioorg Med Chem Lett"},{"key":"10540_CR40","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1016\/j.bmcl.2008.02.026","volume":"18","author":"P Jones","year":"2008","unstructured":"Jones P, Bottomley MJ, Carf\u00ed A et al (2008) 2-Trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitors. Bioorg Med Chem Lett 18:3456\u20133461. https:\/\/doi.org\/10.1016\/j.bmcl.2008.02.026","journal-title":"Bioorg Med Chem Lett"},{"key":"10540_CR41","doi-asserted-by":"publisher","first-page":"4370","DOI":"10.1021\/jm8002894","volume":"51","author":"AP Kozikowski","year":"2008","unstructured":"Kozikowski AP, Tapadar S, Luchini DN et al (2008) Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6. J Med Chem 51:4370\u20134373. https:\/\/doi.org\/10.1021\/jm8002894","journal-title":"J Med Chem"},{"key":"10540_CR42","doi-asserted-by":"publisher","first-page":"5425","DOI":"10.1021\/jm7009217","volume":"50","author":"Y Itoh","year":"2007","unstructured":"Itoh Y, Suzuki T, Kouketsu A et al (2007) Design, synthesis, structure\u2212selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors. J Med Chem 50:5425\u20135438. https:\/\/doi.org\/10.1021\/jm7009217","journal-title":"J Med Chem"},{"key":"10540_CR43","doi-asserted-by":"publisher","first-page":"6078","DOI":"10.1016\/j.bmcl.2008.10.041","volume":"18","author":"R Scarpelli","year":"2008","unstructured":"Scarpelli R, Di Marco A, Ferrigno F et al (2008) Studies of the metabolic stability in cells of 5-(trifluoroacetyl)thiophene-2-carboxamides and identification of more stable class II histone deacetylase (HDAC) inhibitors. Bioorg Med Chem Lett 18:6078\u20136082. https:\/\/doi.org\/10.1016\/j.bmcl.2008.10.041","journal-title":"Bioorg Med Chem Lett"},{"key":"10540_CR44","doi-asserted-by":"publisher","first-page":"6782","DOI":"10.1021\/jm900555u","volume":"52","author":"JM Ontoria","year":"2009","unstructured":"Ontoria JM, Altamura S, Di Marco A et al (2009) Identification of novel, selective, and stable inhibitors of class ii histone deacetylases. Validation studies of the inhibition of the enzymatic activity of HDAC4 by small molecules as a novel approach for cancer therapy. J Med Chem 52:6782\u20136789. https:\/\/doi.org\/10.1021\/jm900555u","journal-title":"J Med Chem"},{"key":"10540_CR45","doi-asserted-by":"publisher","first-page":"3437","DOI":"10.1021\/jm701606b","volume":"51","author":"Y Chen","year":"2008","unstructured":"Chen Y, Lopez-Sanchez M, Savoy DN et al (2008) A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum. J Med Chem 51:3437\u20133448. https:\/\/doi.org\/10.1021\/jm701606b","journal-title":"J Med Chem"},{"key":"10540_CR46","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/cmdc.200700314","volume":"3","author":"AP Kozikowski","year":"2008","unstructured":"Kozikowski AP, Chen Y, Gaysin AM et al (2008) Chemistry, biology, and QSAR studies of substituted biaryl hydroxamates and mercaptoacetamides as HDAC inhibitors\u2014nanomolar-potency inhibitors of pancreatic cancer cell growth. ChemMedChem 3:487\u2013501. https:\/\/doi.org\/10.1002\/cmdc.200700314","journal-title":"ChemMedChem"},{"key":"10540_CR47","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1021\/cb200134p","volume":"7","author":"ES Inks","year":"2012","unstructured":"Inks ES, Josey BJ, Jesinkey SR, Chou CJ (2012) A novel class of small molecule inhibitors of HDAC6. ACS Chem Biol 7:331\u2013339. https:\/\/doi.org\/10.1021\/cb200134p","journal-title":"ACS Chem Biol"},{"key":"10540_CR48","doi-asserted-by":"publisher","first-page":"8387","DOI":"10.1021\/jm101092u","volume":"53","author":"L Auzzas","year":"2010","unstructured":"Auzzas L, Larsson A, Matera R et al (2010) Non-natural macrocyclic inhibitors of histone deacetylases: design, synthesis, and activity. J Med Chem 53:8387\u20138399. https:\/\/doi.org\/10.1021\/jm101092u","journal-title":"J Med Chem"},{"key":"10540_CR49","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.bmcl.2008.12.045","volume":"19","author":"DV Smil","year":"2009","unstructured":"Smil DV, Manku S, Chantigny YA et al (2009) Novel HDAC6 isoform selective chiral small molecule histone deacetylase inhibitors. Bioorg Med Chem Lett 19:688\u2013692. https:\/\/doi.org\/10.1016\/j.bmcl.2008.12.045","journal-title":"Bioorg Med Chem Lett"},{"key":"10540_CR50","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1016\/j.ejmech.2008.11.005","volume":"44","author":"S Dallavalle","year":"2009","unstructured":"Dallavalle S, Cincinelli R, Nannei R et al (2009) Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors. Eur J Med Chem 44:1900\u20131912. https:\/\/doi.org\/10.1016\/j.ejmech.2008.11.005","journal-title":"Eur J Med Chem"},{"key":"10540_CR51","doi-asserted-by":"publisher","first-page":"7836","DOI":"10.1021\/jm900850t","volume":"52","author":"CA Olsen","year":"2009","unstructured":"Olsen CA, Ghadiri MR (2009) Discovery of potent and selective histone deacetylase inhibitors via focused combinatorial libraries of cyclic \u03b13\u03b2-tetrapeptides. J Med Chem 52:7836\u20137846. https:\/\/doi.org\/10.1021\/jm900850t","journal-title":"J Med Chem"},{"key":"10540_CR52","doi-asserted-by":"publisher","first-page":"D198","DOI":"10.1093\/nar\/gkl999","volume":"35","author":"T Liu","year":"2007","unstructured":"Liu T, Lin Y, Wen X et al (2007) BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res 35:D198\u2013D201. https:\/\/doi.org\/10.1093\/nar\/gkl999","journal-title":"Nucleic Acids Res"},{"key":"10540_CR53","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/j.ejmech.2010.02.030","volume":"45","author":"P Bertrand","year":"2010","unstructured":"Bertrand P (2010) Inside HDAC with HDAC inhibitors. Eur J Med Chem 45:2095\u20132116. https:\/\/doi.org\/10.1016\/j.ejmech.2010.02.030","journal-title":"Eur J Med Chem"},{"key":"10540_CR54","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.1016\/j.bmcl.2003.07.012","volume":"13","author":"Y Dai","year":"2003","unstructured":"Dai Y, Guo Y, Curtin ML et al (2003) A novel series of histone deacetylase inhibitors incorporating hetero aromatic ring systems as connection units. Bioorg Med Chem Lett 13:3817\u20133820. https:\/\/doi.org\/10.1016\/j.bmcl.2003.07.012","journal-title":"Bioorg Med Chem Lett"},{"key":"10540_CR55","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1016\/j.bmcl.2010.04.041","volume":"20","author":"H Wang","year":"2010","unstructured":"Wang H, Lim Z-Y, Zhou Y et al (2010) Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: synthesis, SAR, and in vivo antitumor activity. Bioorg Med Chem Lett 20:3314\u20133321. https:\/\/doi.org\/10.1016\/j.bmcl.2010.04.041","journal-title":"Bioorg Med Chem Lett"},{"key":"10540_CR56","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1016\/S0960-894X(01)00552-2","volume":"11","author":"R Lavoie","year":"2001","unstructured":"Lavoie R, Bouchain G, Frechette S et al (2001) Design and synthesis of a novel class of histone deacetylase inhibitors. Bioorg Med Chem Lett 11:2847\u20132850. https:\/\/doi.org\/10.1016\/S0960-894X(01)00552-2","journal-title":"Bioorg Med Chem Lett"},{"key":"10540_CR57","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1016\/j.bmcl.2004.03.018","volume":"14","author":"N Nishino","year":"2004","unstructured":"Nishino N, Yoshikawa D, Watanabe LA et al (2004) Synthesis and histone deacetylase inhibitory activity of cyclic tetrapeptides containing a retrohydroxamate as zinc ligand. Bioorg Med Chem Lett 14:2427\u20132431. https:\/\/doi.org\/10.1016\/j.bmcl.2004.03.018","journal-title":"Bioorg Med Chem Lett"},{"key":"10540_CR58","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1021\/jm030990+","volume":"47","author":"A Mai","year":"2004","unstructured":"Mai A, Massa S, Cerbara I et al (2004) 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 2. Effect of pyrrole-C2 and\/or -C4 substitutions on biological activity. J Med Chem 47:1098\u20131109. https:\/\/doi.org\/10.1021\/jm030990+","journal-title":"J Med Chem"},{"key":"10540_CR59","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.jmgm.2007.10.007","volume":"26","author":"Y Chen","year":"2008","unstructured":"Chen Y, Jiang Y-J, Zhou J-W et al (2008) Identification of ligand features essential for HDACs inhibitors by pharmacophore modeling. J Mol Graph Model 26:1160\u20131168. https:\/\/doi.org\/10.1016\/j.jmgm.2007.10.007","journal-title":"J Mol Graph Model"},{"key":"10540_CR60","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1042\/BJ20021321","volume":"370","author":"AJM de Ruijter","year":"2003","unstructured":"de Ruijter AJM, van Gennip AH, Caron HN et al (2003) Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370:737\u2013749. https:\/\/doi.org\/10.1042\/BJ20021321","journal-title":"Biochem J"},{"key":"10540_CR61","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/43710","volume":"401","author":"MS Finnin","year":"1999","unstructured":"Finnin MS, Donigian JR, Cohen A et al (1999) Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401:188\u2013193. https:\/\/doi.org\/10.1038\/43710","journal-title":"Nature"},{"key":"10540_CR62","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1124\/jpet.103.055541","volume":"307","author":"E Hu","year":"2003","unstructured":"Hu E, Dul E, Sung C-M et al (2003) Identification of novel isoform-selective inhibitors within class I histone deacetylases. J Pharmacol Exp Ther 307:720\u2013728. https:\/\/doi.org\/10.1124\/jpet.103.055541","journal-title":"J Pharmacol Exp Ther"},{"key":"10540_CR63","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/nrd772","volume":"1","author":"RW Johnstone","year":"2002","unstructured":"Johnstone RW (2002) Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1:287\u2013299. https:\/\/doi.org\/10.1038\/nrd772","journal-title":"Nat Rev Drug Discov"},{"key":"10540_CR64","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.jmgm.2007.07.002","volume":"26","author":"S Vadivelan","year":"2008","unstructured":"Vadivelan S, Sinha BN, Rambabu G et al (2008) Pharmacophore modeling and virtual screening studies to design some potential histone deacetylase inhibitors as new leads. J Mol Graph Model 26:935\u2013946. https:\/\/doi.org\/10.1016\/j.jmgm.2007.07.002","journal-title":"J Mol Graph Model"},{"key":"10540_CR65","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1021\/ci800366f","volume":"49","author":"H Tang","year":"2009","unstructured":"Tang H, Wang XS, Huang X-P et al (2009) Novel inhibitors of human histone deacetylase (HDAC) identified by QSAR modeling of known inhibitors, virtual screening, and experimental validation. J Chem Inf Model 49:461\u2013476. https:\/\/doi.org\/10.1021\/ci800366f","journal-title":"J Chem Inf Model"},{"key":"10540_CR66","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1002\/cjoc.200990091","volume":"27","author":"L Yu","year":"2009","unstructured":"Yu L, Liu F, Chen Y, You Q (2009) Pharmacophore identification of hydroxamate HDAC 1 inhibitors. Chin J Chem 27:557\u2013564. https:\/\/doi.org\/10.1002\/cjoc.200990091","journal-title":"Chin J Chem"},{"key":"10540_CR67","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1007\/s00894-008-0350-8","volume":"14","author":"M Chopra","year":"2008","unstructured":"Chopra M, Gupta R, Gupta S, Saluja D (2008) Molecular modeling study on chemically diverse series of cyclooxygenase-2 selective inhibitors: generation of predictive pharmacophore model using catalyst. J Mol Model 14:1087\u20131099. https:\/\/doi.org\/10.1007\/s00894-008-0350-8","journal-title":"J Mol Model"},{"key":"10540_CR68","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1021\/ci050257m","volume":"45","author":"M Chopra","year":"2005","unstructured":"Chopra M, Mishra AK (2005) Ligand-based molecular modeling study on a chemically diverse series of cholecystokinin-B\/gastrin receptor antagonists: generation of predictive model. J Chem Inf Model 45:1934\u20131942. https:\/\/doi.org\/10.1021\/ci050257m","journal-title":"J Chem Inf Model"},{"key":"10540_CR69","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s00894-016-3035-8","volume":"22","author":"P Verma","year":"2016","unstructured":"Verma P, Dalal K, Chopra M (2016) Pharmacophore development and screening for discovery of potential inhibitors of ADAMTS-4 for osteoarthritis therapy. J Mol Model 22:178. https:\/\/doi.org\/10.1007\/s00894-016-3035-8","journal-title":"J Mol Model"},{"key":"10540_CR70","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jmgm.2012.04.003","volume":"37","author":"X Dong","year":"2012","unstructured":"Dong X, Yan J, Du L et al (2012) Pharmacophore identification, docking and \u201cin silico\u201d screening for novel CDK1 inhibitors. J Mol Graph Model 37:77\u201386. https:\/\/doi.org\/10.1016\/j.jmgm.2012.04.003","journal-title":"J Mol Graph Model"},{"key":"10540_CR71","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nchem.1243","volume":"4","author":"GR Bickerton","year":"2012","unstructured":"Bickerton GR, Paolini GV, Besnard J et al (2012) Quantifying the chemical beauty of drugs. Nature Chem 4:90\u201398. https:\/\/doi.org\/10.1038\/nchem.1243","journal-title":"Nature Chem"},{"key":"10540_CR72","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.csbj.2019.02.006","volume":"17","author":"S Pal","year":"2019","unstructured":"Pal S, Kumar V, Kundu B et al (2019) Ligand-based pharmacophore modeling, virtual screening and molecular docking studies for discovery of potential topoisomerase I inhibitors. Comput Struct Biotechnol J 17:291\u2013310. https:\/\/doi.org\/10.1016\/j.csbj.2019.02.006","journal-title":"Comput Struct Biotechnol J"},{"key":"10540_CR73","unstructured":"Bank RPD RCSB PDB: Homepage. https:\/\/www.rcsb.org\/. Accessed 19 Apr 2022"},{"key":"10540_CR74","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/nchembio.2134","volume":"12","author":"Y Hai","year":"2016","unstructured":"Hai Y, Christianson DW (2016) Histone deacetylase 6 structure and molecular basis of catalysis and inhibition. Nat Chem Biol 12:741\u2013747. https:\/\/doi.org\/10.1038\/nchembio.2134","journal-title":"Nat Chem Biol"},{"key":"10540_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2020.127023","volume":"30","author":"JD Osko","year":"2020","unstructured":"Osko JD, Christianson DW (2020) Structural determinants of affinity and selectivity in the binding of inhibitors to histone deacetylase 6. Bioorg Med Chem Lett 30:127023. https:\/\/doi.org\/10.1016\/j.bmcl.2020.127023","journal-title":"Bioorg Med Chem Lett"},{"key":"10540_CR76","doi-asserted-by":"publisher","first-page":"149","DOI":"10.6026\/97320630012149","volume":"12","author":"ST Baby","year":"2016","unstructured":"Baby ST, Sharma S, Enaganti S, Cherian PR (2016) Molecular docking and pharmacophore studies of heterocyclic compounds as Heat shock protein 90 (Hsp90) Inhibitors. Bioinformation 12:149\u2013155. https:\/\/doi.org\/10.6026\/97320630012149","journal-title":"Bioinformation"},{"key":"10540_CR77","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s13660-019-2192-6","volume":"2019","author":"G Yuan","year":"2019","unstructured":"Yuan G, Li T, Hu W (2019) A conjugate gradient algorithm and its application in large-scale optimization problems and image restoration. J Inequal Appl 2019:247. https:\/\/doi.org\/10.1186\/s13660-019-2192-6","journal-title":"J Inequal Appl"},{"key":"10540_CR78","doi-asserted-by":"publisher","first-page":"6609","DOI":"10.3390\/molecules19056609","volume":"19","author":"MK Abdel-Hamid","year":"2014","unstructured":"Abdel-Hamid MK, McCluskey A (2014) In silico docking, molecular dynamics and binding energy insights into the bolinaquinone-clathrin terminal domain binding site. Molecules 19:6609\u20136622. https:\/\/doi.org\/10.3390\/molecules19056609","journal-title":"Molecules"},{"key":"10540_CR79","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1002\/jcc.10306","volume":"24","author":"G Wu","year":"2003","unstructured":"Wu G, Robertson DH, Brooks CL III, Vieth M (2003) Detailed analysis of grid-based molecular docking: a case study of CDOCKER\u2014A CHARMm-based MD docking algorithm. J Comput Chem 24:1549\u20131562. https:\/\/doi.org\/10.1002\/jcc.10306","journal-title":"J Comput Chem"},{"key":"10540_CR80","doi-asserted-by":"publisher","first-page":"3910","DOI":"10.1021\/acs.jctc.0c00145","volume":"16","author":"X Ding","year":"2020","unstructured":"Ding X, Wu Y, Wang Y et al (2020) Accelerated CDOCKER with GPUs, parallel simulated annealing, and fast Fourier transforms. J Chem Theory Comput 16:3910\u20133919. https:\/\/doi.org\/10.1021\/acs.jctc.0c00145","journal-title":"J Chem Theory Comput"},{"key":"10540_CR81","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1002\/jcc.21498","volume":"31","author":"X Li","year":"2010","unstructured":"Li X, Li Y, Cheng T et al (2010) Evaluation of the performance of four molecular docking programs on a diverse set of protein\u2013ligand complexes. J Comput Chem 31:2109\u20132125. https:\/\/doi.org\/10.1002\/jcc.21498","journal-title":"J Comput Chem"},{"key":"10540_CR82","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/nprot.2017.114","volume":"13","author":"Y Li","year":"2018","unstructured":"Li Y, Su M, Liu Z et al (2018) Assessing protein\u2013ligand interaction scoring functions with the CASF-2013 benchmark. Nat Protoc 13:666\u2013680. https:\/\/doi.org\/10.1038\/nprot.2017.114","journal-title":"Nat Protoc"},{"key":"10540_CR83","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jmgm.2004.11.007","volume":"23","author":"A Krammer","year":"2005","unstructured":"Krammer A, Kirchhoff PD, Jiang X et al (2005) LigScore: a novel scoring function for predicting binding affinities. J Mol Graph Model 23:395\u2013407. https:\/\/doi.org\/10.1016\/j.jmgm.2004.11.007","journal-title":"J Mol Graph Model"},{"key":"10540_CR84","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.3892\/mmr.2012.757","volume":"5","author":"P-Y Chen","year":"2012","unstructured":"Chen P-Y, Tsai C-T, Ou C-Y et al (2012) Computational analysis of novel drugs designed for use as acetylcholinesterase inhibitors and histamine H3 receptor antagonists for Alzheimer\u2019s disease by docking, scoring and de novo evolution. Mol Med Rep 5:1043\u20131048. https:\/\/doi.org\/10.3892\/mmr.2012.757","journal-title":"Mol Med Rep"},{"key":"10540_CR85","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.3892\/ol.2018.8873","volume":"16","author":"Y Zhu","year":"2018","unstructured":"Zhu Y, Han Y, Ma Y, Yang P (2018) ADME\/toxicity prediction and antitumor activity of novel nitrogenous heterocyclic compounds designed by computer targeting of alkylglycerone phosphate synthase. Oncol Lett 16:1431\u20131438. https:\/\/doi.org\/10.3892\/ol.2018.8873","journal-title":"Oncol Lett"},{"key":"10540_CR86","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1107\/S0907444904011679","volume":"60","author":"AW Sch\u00fcttelkopf","year":"2004","unstructured":"Sch\u00fcttelkopf AW, van Aalten DMF (2004) PRODRG: a tool for high-throughput crystallography of protein\u2013ligand complexes. Acta Crystallogr D Biol Crystallogr 60:1355\u20131363. https:\/\/doi.org\/10.1107\/S0907444904011679","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10540_CR87","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0091191","volume":"9","author":"WA Cortopassi","year":"2014","unstructured":"Cortopassi WA, Penna-Coutinho J, Aguiar ACC et al (2014) Theoretical and experimental studies of new modified isoflavonoids as potential inhibitors of topoisomerase I from Plasmodium falciparum. PLoS ONE 9:e91191. https:\/\/doi.org\/10.1371\/journal.pone.0091191","journal-title":"PLoS ONE"},{"key":"10540_CR88","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.11261","volume":"9","author":"AK Bepari","year":"2021","unstructured":"Bepari AK, Reza HM (2021) Identification of a novel inhibitor of SARS-CoV-2 3CL-PRO through virtual screening and molecular dynamics simulation. PeerJ 9:e11261. https:\/\/doi.org\/10.7717\/peerj.11261","journal-title":"PeerJ"},{"key":"10540_CR89","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s10495-017-1364-4","volume":"22","author":"M Cosenza","year":"2017","unstructured":"Cosenza M, Civallero M, Marcheselli L et al (2017) Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine. Apoptosis 22:827\u2013840. https:\/\/doi.org\/10.1007\/s10495-017-1364-4","journal-title":"Apoptosis"},{"key":"10540_CR90","doi-asserted-by":"publisher","first-page":"4228","DOI":"10.1182\/blood.V126.23.4228.4228","volume":"126","author":"NS Raje","year":"2015","unstructured":"Raje NS, Bensinger W, Cole CE et al (2015) Ricolinostat (ACY-1215), the first selective HDAC6 inhibitor, combines safely with pomalidomide and dexamethasone and shows promosing early results in relapsed-and-refractory myeloma (ACE-MM-102 study). Blood 126:4228. https:\/\/doi.org\/10.1182\/blood.V126.23.4228.4228","journal-title":"Blood"},{"key":"10540_CR91","doi-asserted-by":"publisher","first-page":"e21075","DOI":"10.1200\/JCO.2016.34.15_suppl.e21075","volume":"34","author":"F Cheng","year":"2016","unstructured":"Cheng F, Laino AS, Wang H et al (2016) In vitro and in vivo anti-melanoma activity of ricolinostat, a selective HDAC6 inhibitor with immunomodulatory properties. JCO 34:e21075\u2013e21075. https:\/\/doi.org\/10.1200\/JCO.2016.34.15_suppl.e21075","journal-title":"JCO"},{"key":"10540_CR92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-018-0788-2","volume":"9","author":"J Cao","year":"2018","unstructured":"Cao J, Lv W, Wang L et al (2018) Ricolinostat (ACY-1215) suppresses proliferation and promotes apoptosis in esophageal squamous cell carcinoma via miR-30d\/PI3K\/AKT\/mTOR and ERK pathways. Cell Death Dis 9:1\u201311. https:\/\/doi.org\/10.1038\/s41419-018-0788-2","journal-title":"Cell Death Dis"},{"key":"10540_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109357","volume":"118","author":"L Li","year":"2019","unstructured":"Li L, Liu F, Huang W et al (2019) Ricolinostat (ACY-1215) inhibits VEGF expression via PI3K\/AKT pathway and promotes apoptosis in osteoarthritic osteoblasts. Biomed Pharmacother 118:109357. https:\/\/doi.org\/10.1016\/j.biopha.2019.109357","journal-title":"Biomed Pharmacother"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-022-10540-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-022-10540-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-022-10540-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T08:37:37Z","timestamp":1695631057000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-022-10540-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,10]]},"references-count":93,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10540"],"URL":"https:\/\/doi.org\/10.1007\/s11030-022-10540-3","relation":{},"ISSN":["1381-1991","1573-501X"],"issn-type":[{"value":"1381-1991","type":"print"},{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,10]]},"assertion":[{"value":"10 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"There was no human or animal experiment conducted for this publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}